
WASHINGTON, Nov. 23 (UPI) -- Peregrine said Wednesday it had signed an agreement to receive $6.7 million in equity financing that it will use to develop Tarvacin and Cotara.
Peregrine, based in Tustin, Calif., said it will sell 8 million shares of stock to an unnamed institutional investor for net proceeds of $6.7 million.
"This is an exciting time for Peregrine as we pursue Tarvacin clinical trials for cancer and hepatitis C, explore its utility in a variety of other viral indications, including influenza, HIV and CMV and collaborate with an academic consortium to further assess the safety and efficacy of Cotara to treat malignant brain cancer," Peregrine President and CEO Steven W. King said in a statement.
"This infusion of capital will enable us to accelerate and expand these efforts," King added.
Peregrine is pursuing three clinical trials involving Tarvacin and Cotara. Both are chimeric antibodies.
|
|
|
|
|
|
| Additional Health News Stories | |
WASHINGTON, May 27 (UPI) --
President Obama has put U.S. foreign policy on auto-pilot while he concentrates on getting re-elected, a senior Republican senator said Sunday.
|
'Men in Black' leads U.S. box office ... Michelle Obama, daughters see Beyonce ... Lady Gaga cancels Jakarta gig for security ... Madonna asks for pool at Israel venue ... News from United Press International.
|
ANCHORAGE, Alaska, May 27 (UPI) --
A black bear didn't go over a river but went to the woods after scampering through residential and industrial areas of Anchorage, Alaska, police said.
|
To avoid a meltdown in 2006, Ford Motor Co. mortgaged the farm putting up its assets – including its Blue Oval logo, and F-150 pickup and iconic Mustang trademarks – to secure $23.5 billion in credit.
|
| Stories | Photos | People | Comments |
View Caption